Gmt Capital Corp Gilead Sciences, Inc. Transaction History

Gmt Capital Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 13, 2019	SELL	$60.54 - $79.0 $8.7 Million - $11.3 Million	-143,660 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $12.7 Million - $14 Million	-177,540 Reduced 55.27%	143,660 $11.1 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $15.3 Million - $17.9 Million	-236,200 Reduced 42.38%	321,200 $22.8 Million
Q4 2017 Feb 12, 2018	SELL	$71.15 - $83.52 $1.52 Million - $1.79 Million	-21,400 Reduced 3.7%	557,400 $39.9 Million
Q3 2017 Nov 09, 2017	BUY	$72.11 - $85.47 $5.6 Million - $6.64 Million	77,700 Added 15.51%	578,800 $46.9 Million
Q2 2017 Aug 14, 2017	BUY	N/A	501,100	501,100 $34.7 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Gmt Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Gmt Capital Corp with notifications on news.